261 related articles for article (PubMed ID: 28691954)
1. Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors.
Iasella CJ; Winstead RJ; Moore CA; Johnson BA; Feinberg AT; Morrell MR; Hayanga JWA; Lendermon EA; Zeevi A; McDyer JF; Ensor CR
Transplantation; 2018 Jan; 102(1):171-177. PubMed ID: 28691954
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
3. Conversion to belatacept after lung transplantation: Report of 10 cases.
Brugière O; Vallée A; Raimbourg Q; Peraldi MN; de Verdière SC; Beaumont L; Hamid A; Zrounba M; Roux A; Picard C; Parquin F; Glorion M; Oniszczuk J; Hertig A; Mal H; Bunel V
PLoS One; 2023; 18(3):e0281492. PubMed ID: 36920935
[TBL] [Abstract][Full Text] [Related]
4. Experience with belatacept rescue therapy in kidney transplant recipients.
Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
[TBL] [Abstract][Full Text] [Related]
5. Belatacept for maintenance immunosuppression in cardiothoracic transplantation: The potential frontier.
Ensor CR; Goehring KC; Iasella CJ; Moore CA; Lendermon EA; McDyer JF; Morrell MR; Sciortino CM; Venkataramanan R; Wiland AM
Clin Transplant; 2018 Oct; 32(10):e13363. PubMed ID: 30058177
[TBL] [Abstract][Full Text] [Related]
6. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
7. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Outcomes after Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant Recipients.
Divard G; Aubert O; Debiais-Deschamp C; Raynaud M; Goutaudier V; Sablik M; Sayeg C; Legendre C; Obert J; Anglicheau D; Lefaucheur C; Loupy A
Clin J Am Soc Nephrol; 2024 May; 19(5):628-637. PubMed ID: 38265815
[TBL] [Abstract][Full Text] [Related]
9. Belatacept for renal rescue in lung transplant patients.
Timofte I; Terrin M; Barr E; Sanchez P; Kim J; Reed R; Britt E; Ravichandran B; Rajagopal K; Griffith B; Pham S; Pierson RN; Iacono A
Transpl Int; 2016 Apr; 29(4):453-63. PubMed ID: 26678245
[TBL] [Abstract][Full Text] [Related]
10. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
[TBL] [Abstract][Full Text] [Related]
11. Does belatacept improve outcomes for kidney transplant recipients? A systematic review.
Talawila N; Pengel LH
Transpl Int; 2015 Nov; 28(11):1251-64. PubMed ID: 25965549
[TBL] [Abstract][Full Text] [Related]
12. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
[TBL] [Abstract][Full Text] [Related]
13. Arterial stiffness in kidney transplantation: a single center case-control study comparing belatacept versus calcineurin inhibitor immunosuppressive based regimen.
Melilli E; Bestard-Matamoros O; Manonelles-Montero A; Sala-Bassa N; Mast R; Grinyó-Boira JM; Cruzado JM
Nefrologia; 2015; 35(1):58-65. PubMed ID: 25611834
[TBL] [Abstract][Full Text] [Related]
14. Switching renal transplant recipients to belatacept therapy: results of a real-life gradual conversion protocol.
Malvezzi P; Fischman C; Rigault G; Jacob MC; Raskovalova T; Jouve T; Janbon B; Rostaing L; Cravedi P
Transpl Immunol; 2019 Oct; 56():101207. PubMed ID: 31071442
[TBL] [Abstract][Full Text] [Related]
15. Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2): a retrospective cohort study.
Bertrand D; Matignon M; Morel A; Ludivine L; Lemoine M; Hanoy M; Roy FL; Nezam D; Hamzaoui M; de Nattes T; Moktefi A; François A; Laurent C; Etienne I; Guerrot D
Nephrol Dial Transplant; 2023 Feb; 38(2):481-490. PubMed ID: 35544123
[TBL] [Abstract][Full Text] [Related]
16. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
[TBL] [Abstract][Full Text] [Related]
17. An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Webber AB; Vincenti F
Transplantation; 2016 Apr; 100(4):836-43. PubMed ID: 27003097
[TBL] [Abstract][Full Text] [Related]
18. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
[TBL] [Abstract][Full Text] [Related]
19. Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States.
Karadkhele G; Duneton C; Garro R; Badell IR; Pearson TC; Larsen CP; Hogan J
Clin Transplant; 2022 Mar; 36(3):e14531. PubMed ID: 34757651
[TBL] [Abstract][Full Text] [Related]
20. Optimization of de novo belatacept-based immunosuppression administered to renal transplant recipients.
Kirk AD; Adams AB; Durrbach A; Ford ML; Hildeman DA; Larsen CP; Vincenti F; Wojciechowski D; Woodle ES
Am J Transplant; 2021 May; 21(5):1691-1698. PubMed ID: 33128812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
